Jennifer H. Martin
#141,346
Most Influential Person Now
Australian clinical pharmacologist, physician and academic
Jennifer H. Martin's AcademicInfluence.com Rankings
Jennifer H. Martinmedical Degrees
Medical
#3442
World Rank
#3910
Historical Rank
Pharmacology
#455
World Rank
#510
Historical Rank
Jennifer H. Martinphilosophy Degrees
Philosophy
#10372
World Rank
#14208
Historical Rank
Logic
#7492
World Rank
#9271
Historical Rank
Download Badge
Medical Philosophy
Jennifer H. Martin's Degrees
- PhD Pharmacology University of Melbourne
Why Is Jennifer H. Martin Influential?
(Suggest an Edit or Addition)According to Wikipedia, Jennifer Helen Martin is an Australian clinical pharmacologist, physician and academic. She is chair of Clinical Pharmacology in the University of Newcastle School of Medicine and Public Health, Director of the NHMRC funded Australian Centre for Cannabinoid Clinical and Research Excellence , and an elected a Fellow of the Australian Academy of Health and Medical Sciences. Martin translates research into practice and policy. Her research involves the investigation of therapeutic drugs, from drug design and development, to clinical trials and studies to investigate how new drugs perform in the general population.
Jennifer H. Martin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Reducing inappropriate polypharmacy: the process of deprescribing. (2015) (984)
- Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis (2010) (828)
- Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats (2003) (311)
- Therapeutic drug monitoring of antimicrobials. (2012) (265)
- Resveratrol does not benefit patients with nonalcoholic fatty liver disease. (2014) (234)
- Assessment of nonischemic myocardial fibrosis. (2010) (223)
- Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. (2010) (181)
- Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. (2017) (157)
- Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. (2003) (155)
- Association of Imaging Markers of Myocardial Fibrosis With Metabolic and Functional Disturbances in Early Diabetic Cardiomyopathy (2011) (145)
- Minimizing inappropriate medications in older populations: a 10-step conceptual framework. (2012) (120)
- A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects (2019) (116)
- Resveratrol--pills to replace a healthy diet? (2011) (116)
- Deciding when to stop: towards evidence-based deprescribing of drugs in older populations (2012) (115)
- Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. (2005) (115)
- Marked increase in proton pump inhibitors use in Australia (2010) (109)
- The development and evaluation of an oncological palliative care deprescribing guideline: the ‘OncPal deprescribing guideline’ (2014) (106)
- Using routine inpatient data to identify patients at risk of hospital readmission (2009) (98)
- Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial (2018) (86)
- Polypharmacy among inpatients aged 70 years or older in Australia (2015) (85)
- The role of the GP in follow-up cancer care: a systematic literature review (2016) (78)
- A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. (2019) (75)
- Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients (2014) (72)
- Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies (2020) (71)
- Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease (2015) (70)
- IN VITRO INHIBITORY EFFECTS OF ATORVASTATIN ON CARDIAC FIBROBLASTS: IMPLICATIONS FOR VENTRICULAR REMODELLING (2005) (69)
- Can paracetamol (acetaminophen) be administered to patients with liver impairment? (2016) (66)
- Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects (2018) (66)
- (+)-epi-α-Bisbolol Is the Wound-Healing Principle of Peperomia galioides: Investigation of the in Vivo Wound-Healing Activity of Related Terpenoids (2001) (61)
- Diagnostic errors in older patients: a systematic review of incidence and potential causes in seven prevalent diseases (2016) (59)
- Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class (2003) (58)
- Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches (2014) (58)
- Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. (2007) (56)
- Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect (2021) (53)
- Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future (2015) (52)
- Fibrosis as a therapeutic target post-myocardial infarction. (2005) (51)
- Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users (2018) (49)
- Aiming to be NEAT: safely improving and sustaining access to emergency care in a tertiary referral hospital. (2014) (49)
- The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells (2015) (45)
- Drug‐Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles (2019) (44)
- Drug-associated pulmonary arterial hypertension (2018) (41)
- “LONG COVID”—A hypothesis for understanding the biological basis and pharmacological treatment strategy (2022) (40)
- Alcohol-attributable mortality in Ireland. (2010) (38)
- Repurposing some older drugs that cross the blood–brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma (2016) (38)
- Current Status of Therapeutic Drug Monitoring in Australia and New Zealand: A Need for Improved Assay Evaluation, Best Practice Guidelines, and Professional Development (2010) (38)
- Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome (2016) (36)
- Quality of drug interaction alerts in prescribing and dispensing software (2009) (35)
- Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology. (2012) (34)
- Longitudinal patterns of breast cancer screening: mammography, clinical, and breast self-examinations in a rural and urban setting. (2014) (33)
- Usefulness of at rest and exercise hemodynamics to detect subclinical myocardial disease in type 2 diabetes mellitus. (2011) (33)
- Defining and classifying terminology for medication harm: a call for consensus (2018) (33)
- Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers (2014) (32)
- Individualised medicine: why we need Bayesian dosing (2017) (31)
- Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction? (2018) (31)
- Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD) (2019) (31)
- Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. (2002) (29)
- Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method (2015) (29)
- Medication‐Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention (2019) (28)
- Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review (2012) (28)
- Statins and clinical outcomes in heart failure. (2007) (28)
- Prevalence of medication discrepancies in patients with cirrhosis: a pilot study (2016) (27)
- The Effects of Tai Chi in Centrally Obese Adults with Depression Symptoms (2015) (27)
- Optimising Low Dose Methotrexate for Rheumatoid Arthritis - A Review. (2019) (26)
- Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia (2015) (25)
- Reducing the burden of cancer for Aboriginal and Torres Strait Islander Australians: time for a coordinated, collaborative, priority‐driven, Indigenous‐led research program (2011) (25)
- Cytochrome P450 drug interactions: are they clinically relevant? (2001) (25)
- Efficacy of nitazoxanide against experimental cryptosporidiosis in goat neonates (2007) (24)
- Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis (2017) (24)
- Altered sympathetic and parasympathetic activity in lung transplantation patients at rest and following autonomic perturbation. (2002) (24)
- Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women (2014) (23)
- Impact of dose-rate on the low-dose hyper-radiosensitivity and induced radioresistance (HRS/IRR) response (2013) (23)
- When less is more – efficacy with less toxicity at the ED50 (2017) (22)
- Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. (2014) (22)
- Pharmacokinetic‐Guided Dosing of New Oral Cancer Agents (2017) (22)
- Target Concentration Intervention in Oncology: Where Are We At? (2012) (22)
- eGFR — use beyond the evidence (2009) (21)
- Smoking and drug interactions (2013) (21)
- Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours (2016) (21)
- A Validated Method for the Detection of 32 Bath Salts in Oral Fluid. (2017) (21)
- A Validated Method for the Detection of Synthetic Cannabinoids in Oral Fluid. (2018) (20)
- Cytochrome P450 drug interactions (2001) (20)
- Association of diabetes with survival among cohorts of Indigenous and non-Indigenous Australians with cancer (2008) (20)
- Optimising care of patients with chronic disease: patient‐oriented education may improve disease knowledge and self‐management (2017) (19)
- Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling (2018) (19)
- Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) (2020) (19)
- Reduced End-Systolic Pressure-Volume Ratio Response to Exercise: A Marker of Subclinical Myocardial Disease in Type 2 Diabetes (2010) (18)
- Factors Associated With Cancer-Specific and Overall Survival Among Indigenous and Non-Indigenous Gynecologic Cancer Patients in Queensland, Australia: A Matched Cohort Study (2014) (17)
- Australasian Chapter of Sexual Health Medicine (2010) (17)
- Effects of a drug minimization guide on prescribing intentions in elderly persons with polypharmacy. (2012) (16)
- Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial (2017) (16)
- Pharmacogenetics of warfarin - is testing clinically indicated? (2009) (16)
- Quality of drug interaction alerts in prescribing and dispensing software (2009) (16)
- The future of thiopurine pharmacogenomics. (2012) (16)
- Breast cancer diagnosis, patterns of care and burden of disease in Queensland, Australia (1998–2004): does being Indigenous make a difference? (2016) (14)
- BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin. (2013) (13)
- Gentamicin Monitoring Practices in Teaching Hospitals - Time to Undertake the Necessary Randomised Controlled Trial (2012) (13)
- Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. (2018) (13)
- Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor (2021) (13)
- Medicines optimisation in older people: Taking age and sex into account. (2016) (13)
- Valproate in Adjuvant Glioblastoma Treatment. (2016) (12)
- Drug repurposing in the era of COVID‐19: a call for leadership and government investment (2020) (12)
- Precision dosing of targeted anticancer drugs—challenges in the real world (2017) (12)
- Determination of a suitable voriconazole pharmacokinetic model for personalised dosing (2016) (12)
- Pharmacovigilance and expedited drug approvals. (2018) (12)
- Community-identified recommendations to enhance cancer survivorship for Aboriginal and Torres Strait Islander people. (2018) (12)
- Achieving the World Health Organization's vision for clinical pharmacology (2016) (12)
- Parasitic pharmacology: A plausible mechanism of action for cannabidiol (2019) (11)
- Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. (2021) (11)
- Ensuring access to safe, effective, and affordable cannabis‐based medicines (2020) (10)
- Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID‐19 and response to treatment (2022) (10)
- Khat‐associated hepatitis (2013) (10)
- Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target (2021) (10)
- Ezetimibe: Use, costs, and adverse events in Australia (2017) (10)
- Translational hurdles with cannabis medicines (2020) (9)
- Role of statins in diabetes complications. (2009) (9)
- Unmet supportive care needs among people with cancer: A cross-cultural comparison between Indigenous and Non-Indigenous Australians. (2019) (9)
- The rationale of dose-response curves in selecting cancer drug dosing. (2019) (9)
- Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy. (2014) (9)
- Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction. (2010) (9)
- Exploring Positive Survivorship Experiences of Indigenous Australian Cancer Patients (2018) (9)
- Barriers and Challenges in Performing Pharmacokinetic Studies to Inform Dosing in the Neonatal Population (2020) (9)
- Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology (2021) (9)
- Clinical trials with cannabis medicines—guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience (2020) (8)
- Spotlight Commentary: Model-informed precision dosing must demonstrate improved patient outcomes. (2019) (8)
- The hazards of rapid approval of new drugs. (2016) (8)
- Medicinal cannabis in Australia: the missing links (2016) (8)
- Rural-urban disparities in stage of breast cancer at diagnosis in Australian women. (2016) (8)
- Compassion and evidence in prescribing cannabinoids: a perspective from the Royal Australasian College of Physicians (2018) (8)
- Vancomycin therapeutic drug monitoring in paediatrics (2019) (7)
- Identification of Australian Aboriginal and Torres Strait Islander Cancer Patients in the Primary Health Care Setting (2017) (7)
- HLA-A*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds (2015) (7)
- Model‐based analysis on systemic availability of co‐administered cannabinoids after controlled vaporised administration (2020) (7)
- A Simple Isocratic HPLC Method for the Quantitation of 17 Cannabinoids (2021) (7)
- The Impact of Model-Misspecification on Model Based Personalised Dosing (2016) (6)
- A new frontier in haematology – combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug (2014) (6)
- Stability of plasma creatinine concentrations in acute complex long-stay admissions to a general medical service. (2010) (6)
- A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID‐19 (2020) (6)
- Effects of a Drug Minimization Guide on Prescribing Intentions in Elderly Persons with Polypharmacy (2012) (6)
- Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes. (2015) (6)
- Effectiveness of patient‐oriented education and medication management intervention in people with decompensated cirrhosis (2020) (6)
- A pilot study to assess the appropriateness of prescribing from a collaborative pharmacist prescribing study in a surgical pre admission clinic (2014) (6)
- Buying time: Drug repurposing to treat the host in COVID‐19H (2020) (6)
- Patterns of primary health care service use of Indigenous Australians diagnosed with cancer (2019) (6)
- "I'm a Survivor": Aboriginal and Torres Strait Islander Cancer Survivors' Perspectives of Cancer Survivorship. (2018) (6)
- Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study (2021) (6)
- Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma? (2015) (6)
- Drug development: The use of unlicensed/off-label medicines in pediatrics. (2012) (6)
- Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting (2018) (5)
- Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes (2020) (5)
- Care and concern with cannabinoids used therapeutically (2018) (5)
- Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. (2011) (5)
- Overcoming barriers to implementing precision dosing with 5‐fluorouracil and capecitabine (2021) (5)
- Immunotherapy for HPV associated pre-cancer (2003) (5)
- Clinical Consequences of a Miscalibrated Digoxin Immunoassay (2015) (4)
- Communication, Collaboration and Care Coordination: The Three-Point Guide to Cancer Care Provision for Aboriginal and Torres Strait Islander Australians (2020) (4)
- Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients (2019) (4)
- Doctors and the pharmaceutical industry: time for a national policy? (2009) (4)
- How ‘Optimal’ are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations (2016) (4)
- Comorbidities amongst Indigenous Cancer Patients: Impact on Treatment and Survival. (2014) (4)
- Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial (2022) (4)
- Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50 (ED50). (2019) (4)
- Lipid and other management to improve arterial disease and survival in end stage renal disease (2017) (4)
- Clinical research in synthetic cannabinoids ‐ do we need a national approach? (2014) (4)
- Precision medicine‐based drug treatment individualization in oncology (2020) (4)
- A practical treatment for COVID‐19 and the next pandemic (2022) (4)
- Expert advice for prescribing cannabis medicines for patients with epilepsy—drawn from the Australian clinical experience (2022) (4)
- A Simple and Sensitive LC-MS/MS Method for the Simultaneous Determination of Cyclophosphamide and Doxorubicin Concentrations in Human Plasma (2017) (4)
- Lack of efficacy of cannabidiol for relieving back pain: time to re‐set expectations? (2021) (3)
- Hyperglycemia has a detrimental effect on cardiac remodelling and mortality after myocardial infarction: benefit of statin therapy (2006) (3)
- Obesity and COVID-19: renin–angiotensin as a mediator of morbidity and mortality (2021) (3)
- Enabling the success of academic health science centres in Australia: where is the leadership? (2014) (3)
- Suggestions for Improving the Characterization of Risk from Exposures to Per and Polyfluorinated Alkyl Substances (2020) (3)
- Communication, Collaboration and Care Coordination: The Three-Point Guide to Cancer Care Provision for Aboriginal and Torres Strait Islander Australians (2020) (3)
- Reporting adverse drug events to the Therapeutic Goods Administration (2021) (3)
- Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model (2021) (3)
- Clinical benefits of evolocumab appear less than hoped (2018) (3)
- DRUG REPURPOSING—Overcoming the translational hurdles to clinical use (2019) (3)
- Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS. (2021) (3)
- New medicines — urgent need to assess outcomes in special groups (2012) (3)
- Predicting drug interactions in addiction treatment (2017) (3)
- Drug repurposing in the era of COVID – a market failure needing leadership and government investment (2020) (3)
- Heterogeneity in tumour content and necrosis in primary lung cancers: Implications for molecular analysis (2013) (2)
- Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain (2018) (2)
- Weight‐based tacrolimus trough concentrations post liver transplant (2019) (2)
- Optimising Drug Use in Elderly Populations - Pilot Study of a Drug Minimization Guide (2011) (2)
- Policy change to improve pathology turnaround time and reduce costs – possible to do both? (2013) (2)
- The Development of a Rapid, Simple and Sensitive LC-MS/MS Method, to Guide Clinical Dosing, for the Analysis of 5-Fluorouracil in Human Plasma (2017) (2)
- Backscatter, T1 mapping or pro-collagen biomarkers for non-invasive assessment of treatment response to anti-fibrotic therapy in subclinical diabetic cardiomyopathy? A randomized trial (2012) (2)
- The HEART FAILURE Journal Club: a review of publications on heart failure in American Heart Journal (2001) (2)
- Diamantina Health Partners: integrating leadership in research, research translation, education and clinical care (2012) (2)
- Statins and congestive heart failure (2008) (2)
- Aboriginal and Torres Strait Islander patients' cancer care pathways in Queensland: insights from health professionals. (2021) (2)
- Indigenous women with gynaecological cancers have poorer survival than Non-Indigenous women: explained by stage, comorbidity and treatment uptake (2012) (2)
- Cannabidiol drug interaction considerations for prescribers and pharmacists (2022) (2)
- Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells (2022) (2)
- From an evolutionary perspective, all ‘new’ antimicrobial targets are old: time to think outside the box (2015) (2)
- Drug-induced injury due to flucloxacillin: relevance of multiple HLA alleles (2018) (2)
- Discrepancies in the use of medications in patients with cirrhosis (2015) (1)
- Critical insights to COVID‐19 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacology (2022) (1)
- Early Diagnosis and Improved Treatment Uptake in the First Year may Reduce Survival Disparities between Aboriginal and Torres Strait Islander and other Australian Women Diagnosed with Gynaecological Cancer (2014) (1)
- Chapter 85 – Novel Drug Treatments for Hypertension (2007) (1)
- Optimal cancer drug dosing in adolescents: new issues and the old unaddressed ones (2018) (1)
- 940-P: 14C-Tirzepatide ADME Studies in Rat and Monkey (2020) (1)
- Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis (2022) (1)
- The challenge of discharge: combining medication reconciliation and discharge planning (2017) (1)
- Polypharmacy among older inpatients in Australia (2013) (1)
- Reduced Pressure-Volume Response to Exercise: A Marker of Subclinical Myocardial Disease in Type 2 Diabetes (2010) (1)
- Prescribing Skills Assessment – initial results from an Australian cross-institutional pilot (2018) (1)
- Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50 (2019) (1)
- Breast cancer diagnosis and patterns of treatment: does being Indigenous make a difference? (2012) (1)
- Chachay et al 2014 Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease (2016) (1)
- Intensive lipid‐lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis (2019) (1)
- The challenge of costly drugs. (2016) (1)
- Cannabinoid Toxicity Post Therapeutic Intraperitoneal Injection (2017) (1)
- Safety and efficacy of statins (2017) (1)
- Author Correction: Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction? (2018) (1)
- Use of complementary and alternative medicines in people with depression and central obesity: Findings from a Tai Chi and Qigong study (2017) (1)
- Association of Imaging Markers of Myocardial Fibrosis with Metabolic and Functional Disturbances in Early Diabetic Cardiomyopathy: A Multi-modality Study (2011) (1)
- Did our pharmacological strategy for COVID‐19 fail? (2021) (1)
- Medication adherence in outpatients with decompensated cirrhosis (2016) (1)
- Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites (2021) (1)
- Insulin Analogues: Reviewing the Pros and Cons in Managing Diabetes Mellitus (2011) (1)
- Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients (2014) (1)
- Drug Use Evaluation Services in Australia and New Zealand: a Neglected Area of Research? (2010) (1)
- Dried Blood Spot Sampling in the Monitoring of Anticancer Therapy for Solid Tumors: A Systematic Review. (2023) (0)
- Supporting Aboriginal and Torres Strait Islander people diagnosed with cancer to navigate the healthcare system (2014) (0)
- The Efficacy of the Regionalized Trauma Center in Decreasing Mortality in the Trauma Patient (2009) (0)
- Effect of Ligand Size On Uptake Andwashout of Epha2 Targeted Theranostics From Glioblastomas Using 64Cu-Pet (2016) (0)
- Relationship between obese women with breast cancer, their socioeconomic status and comorbidities (2014) (0)
- Polypharmacy is Associated with High-Risk Medication-Related Problems in People with Decompensated Cirrhosis (2017) (0)
- Melanoma: An immunotherapy journey from bench to bedside. (2022) (0)
- Differences in breast cancer screening patterns between women residing rural and urban areas (2013) (0)
- University of Dundee Association of Liver Injury From Specific Drugs , or Groups of Drugs , With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study (0)
- Use of Ezetimibe in Australia (2014) (0)
- Taking the brake off the immune system: Hypotheses, trials, tribulations, and the evolving discipline of clinical immunopharmacology (2020) (0)
- Pharmacogenomics and warfarin therapy (2012) (0)
- Obesity a Risk Factor for Chemotherapy Dose Reduction in Breast Cancer: a Multi-Centered Approach (2014) (0)
- High-risk medication-related problems are prevalent in people with decompensated cirrhosis (2017) (0)
- An unusual cause of post-infectious glomerulonephritis (2007) (0)
- Screening lung Tumour tissue for whole genome sequencing (2012) (0)
- A pilot study to assess the appropriateness of prescribing from a randomised controlled trial of collaborative prescribing in a surgical pre admission clinic (2014) (0)
- Comment on a paper by Dupoiron et al. “A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐ naloxone (up to 160/80 mg daily) versus oxycodone PR” (2017) (0)
- OC's - emotional journalism? (1999) (0)
- Assessment of adequacy of loading dose of phenytoin (PTN) in adult intensive care patients using population pharmacokinetics (2010) (0)
- 525 BMI BUT NOT AETIOLOGY OR STAGE OF LIVER DISEASE AFFECTS THE DIAGNOSTIC SENSITIVITY OF CARBOHYDRATE DEFICIENT TRANSFERRIN (2013) (0)
- Selected state of the art research in internal medicine, 2017 (2018) (0)
- A survey of therapeutic drug monitoring in Australia and New Zealand (2008) (0)
- Development of an UHPLC-MS/MS method for remifentanil quantification in a small plasma volume (2019) (0)
- Medication beliefs predict low medication adherence in people with decompensated cirrhosis (2017) (0)
- Title : Association of Liver Injury From Specific Drugs , or Groups of Drugs , With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study (2016) (0)
- Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety (2021) (0)
- Are general practitioners getting the information they need from hospitals and specialists to provide quality cancer care for Indigenous Australians? (2020) (0)
- The Improvement of Memory Deficits in a Familiar Mouse Model of Alzheimer’s Disease due to Prolonged Treatment with Tetrahydrocannabinol (2018) (0)
- Reply (2019) (0)
- Letter: The challenge of costly drugs (2016) (0)
- An exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia [Conference Abstract] (2015) (0)
- Preliminary results of a therapeutic drug monitoring survey in Australasia (2009) (0)
- Easier patient access to medical cannabis carries risks as well as benefits (2021) (0)
- Cannabis, hallucinogens and CNS stimulants (2003) (0)
- Higher dose statins after stroke (2021) (0)
- Pharmacology Research & Perspectives calls for pharmacology education papers (2021) (0)
- The Impact of Model-Misspecification on Model Based Personalised Dosing (2016) (0)
- Letters to the Editor (2009) (0)
- Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs (2022) (0)
- Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition (2023) (0)
- Clinically Optimal Versus "Target" Doses in Heart Failure. (2019) (0)
- Epha2 Antibody Increases Sensitivity of U87 Glioblastoma Cells to Irradiation (2015) (0)
- Electrocardiogaffe (2022) (0)
- Determination of a suitable voriconazole pharmacokinetic model for personalised dosing (2015) (0)
- Trading Lower HbA1c for Increased Adverse Events: A Zero Sum Game? (2016) (0)
- Pharmacology Research & Perspectives: A Decade of Progress (2023) (0)
- Science and art of anticancer drug dosing: nine steps to personalised therapy (2020) (0)
- Evidence-practice gaps for Australian General Practitioners (GP) in assisting pregnant women to quit (2015) (0)
- EP-1416 Palliative Oesophageal Chemoradiotherapy: A Phase 1 Clinical Trial (2019) (0)
- Effect of pharmaceutical regulatory policy on health impact (2020) (0)
- Statin doses after acute coronary syndrome (2022) (0)
- Complementary and alternative therapies in the palliative setting (2022) (0)
- Medicinal cannabis in Australia: the missing links (2016) (0)
- High-Dose Statins Increase Adverse Events and Do Not Improve Survival. (2022) (0)
- What do GPS in QLD really think about community based HCV prescribing (2008) (0)
- Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs, volume II (2023) (0)
- Design and conformational analysis of several highly potent bradykinin receptor antagonists. [Erratum to document cited in CA114(15):144010y] (1993) (0)
- Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome some of the Challenges of Developing Medicinal Cannabis from Botanical Origins. (2020) (0)
- Cannabinoid use in practice in Australasia-Better guidance and new drug information systems will be essential for prescribers. (2019) (0)
- Drug prices not the whole story (2000) (0)
- Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites (2021) (0)
- On strongly unimodal third-order SISO linear systems with applications to pharmacokinetics (2020) (0)
- Interactions between antihypertensive drugs and other medications (2007) (0)
- Relationship of pro-collagen biomarkers of myocardial fibrosis with myocardial dysfunction and metabolic derangement in type 2 diabetes (2012) (0)
- Non-invasive Quantification of Myocardial Fibrosis in Diabetic Cardiomyopathy: T1 Mapping or Integrated Backscatter? (2010) (0)
- Rapidly Progressive Severe Amiodarone‐Induced Hypothyroidism in an Elderly Female (2009) (0)
- Is backscatter a function-independent method for assessment of treatment response to anti-fibrotic therapy in subclinical diabetic cardiomyopathy? Validation against T1 mapping and collagen biomarkers (2012) (0)
- POTENTIAL ADVERSE EFFECTS FROM STATINS Lowering cholesterol with statins compared with innately low cholesterol (2007) (0)
- Introduction (2017) (0)
- College conferences: time for merit‐based selection of speakers and educators? (2020) (0)
- Issues of Pharmacogenomics in Monitoring Warfarin Therapy (2016) (0)
- EPIDEMIOLOGY Alcohol-Attributable Mortality in Ireland (2010) (0)
- Medical experts warn Australia's understanding of medicinal cannabis lacking (2016) (0)
- Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial (2022) (0)
- Tranilast dose-dependently attenuates extra-cellular matrix deposition in rats. (2004) (0)
- Myocardial dysfunction and metabolic derangement in Type 2 Diabetes: Relationship with procollagen biomarkers of myocardial fibrosis (2011) (0)
- Editorial for the “Precision Medicine-based Drug Treatment Individualization in Oncology” themed issue Precision Medicine-based Drug Treatment Individualization in Oncology - THEMED ISSUE EDITORAL (2020) (0)
- A PHARMACOLOGICAL FRAMEWORK FOR INTEGRATING TREATING THE HOST, REPUPOSING AND THE DAMAGE RESPONSE FRAMEWORK IN COVID19 DISEASE (2020) (0)
- Gentamicin Use - More Clinical Outcome Evidence Needed (2012) (0)
- Radiation-induced persistent DNA damage response and late toxicity in cardiac tissue (2023) (0)
- Drug use evaluation systems in Australasia – what’s new? (2008) (0)
- A Randomised Trial of Spironolactone use in Subclinical Diabetic Cardiomyopathy: Anti-Fibrotic Effects on Myocardial Structure and Function (2012) (0)
- Statin therapy in the prevention and treatment of heart failure (2009) (0)
- A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma (2023) (0)
- Metabolic comorbid conditions in chronic heart failure: diabetes and hypercholesterolaemia (2003) (0)
- Abstract 16723: Impaired Exercise Capacity in Diabetes: Procollagen Biomarkers Suggest Mechanism is Underlying Myocardial Fibrosis (2010) (0)
- Defining the trials nurses’ role in operationalising a medicinal cannabis clinical trial (2021) (0)
- Medicinal cannabis prescribing guidance documents: An evidence-based, best-practice framework based on the New South Wales experience (2022) (0)
- Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: a randomised, double blind, placebo-controlled trial (2013) (0)
- Pharmacokinetics, safety, and tolerability of a THC:CBD oil formulation in patients with chronic non-cancer pain on long term high dose opioid analgesia. (2021) (0)
- Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children. (2022) (0)
- Relationship of Biomarkers of Myocardial Fibrosis with Myocardial Dysfunction and Metabolic Derangement in Type 2 Diabetes (2012) (0)
- Subclinical Myocardial Disease in Type 2 Diabetes: Mechanistic Insights from Resting and Exercise Haemodynamics (2010) (0)
- Does protein kinase CR (PKCP) inhibition directly reduce collagen production from cardiac fibroblasts (2004) (0)
This paper list is powered by the following services:
Other Resources About Jennifer H. Martin
What Schools Are Affiliated With Jennifer H. Martin?
Jennifer H. Martin is affiliated with the following schools:
